Atara Biotherapeutics

Canaccord Genuity Acted as a Lead Manager in a Follow-On Offering for Atara Biotherapeutics, Inc.

Transaction Overview:

Atara Biotherapeutics, Inc. (the “Company”) (Nasdaq:ATRA), priced its $175 million public offering on December 8, 2020 at a price of $24.50 per share. The Company issued 5,102,041 shares of common stock and pre-funded warrants to purchase an aggregate of 7,142,857 shares of common stock at a purchase price of $24.4999 per pre-funded share.    

Company Overview:
Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.